Clinical Trial Update: Efficacy and Safety of Naftopidil in Patient With Neurogenic Lower Urinary Tract Dysfunction Not Caused by Benign Prostatic Hyperplasia [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update assessing the efficacy and safety of naftopidil in patients with neurogenic lower urinary tract dysfunction not caused by BPH.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neurogenic Lower Urinary Tract Dysfunction

Drugs mentioned

• Naftopidil (Naftopidil)

Snippet

Sponsor: Samsung Medical Center | Conditions: Neurogenic Lower Urinary Tract Dysfunction | Phase 4 | Status: COMPLETED